Elixirgen Scientific

What Elixirgen Scientific does

Elixirgen Scientific, founded in 2016 and based in Baltimore, Maryland, is a biotechnology company specializing in induced pluripotent stem cell (iPSC) differentiation technology for drug discovery and disease modeling. In July 2025, the company rebranded as Ricoh Biosciences, Inc. and now operates as a wholly-owned subsidiary of Ricoh Group, a Japanese multinational conglomerate. The company develops and commercializes iPSC-derived human cell products across nine distinct neural cell types—excitatory, cholinergic, dopaminergic, GABAergic, motor, and sensory neurons, plus astrocytes, microglia, and neural precursor cells—using proprietary SeV (Sendai virus) and mRNA-based differentiation protocols that produce functional cells in 1-2 weeks.

The core technical platform, branded as the Target Phenotype Platform, employs transcriptomic benchmarking via bulk and single-cell RNA-seq data to establish quantitative differentiation standards covering lineage-defining markers, functionally relevant genes, and developmental regulators. Culture optimization combines defined media, small molecules, and timed induction strategies to ensure reproducibility across multiple donors and lots. The company complements its catalog with six service lines: custom iPSC differentiation, novel cell type development, disease modeling (ALS and Alzheimer's), custom assay services, multielectrode array (MEA) electrophysiology, and calcium flux assays.

The business model is hybrid: catalog products (iPSC-derived cells, differentiation kits, and maintenance media/reagents) sell through self-serve e-commerce globally, while custom services are delivered through direct sales engagement. Distribution combines direct e-commerce with a partner network, including a dedicated Japan storefront. Primary customer segments are pharmaceutical and biotech companies engaged in drug discovery, ADMET testing, and compound screening, alongside academic and research institutions, with particular emphasis on neuroscience and neurodegeneration researchers. Founder and Chief Scientific Officer Minoru Ko leads the scientific direction. The company is privately held, with no public revenue or funding data disclosed.

Name

Elixirgen Scientific

Legal name

Ricoh Biosciences, Inc.

Website

https://elixirgenscientific.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Elixirgen Scientific (rebranded as Ricoh Biosciences in July 2025) is a Baltimore-based biotechnology subsidiary of Ricoh Group that develops iPSC-derived human neural cells, differentiation kits, and custom services for pharmaceutical drug discovery and academic neuroscience research.

Ownership category

akta.pro rank

Product category

iPSC-based drug discovery products and services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

Keywords

• IPSC cell products
• Stem cell technology
• Drug discovery services
• Neuron differentiation kits
• Disease modeling

Headquarters

HQ city

Baltimore

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. iPSC Products: Sale of iPSC-derived cells (neurons, astrocytes, microglia), differentiation kits, and maintenance media/reagents. Products sold as catalog items through e-commerce.
2. Custom iPSC Differentiation Services: Custom differentiation services where customers provide their cell lines and Ricoh applies proprietary protocols to generate desired cell types, typically completed in weeks.
3. Novel Cell Type Development: Development of new cell types when no existing products meet customer research needs, involving custom R&D and protocol development.
4. Custom Assay Services: MEA (Multielectrode Array) and Calcium Flux Assays using customer-provided or company-provided cells to generate phenotypic data for drug discovery.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

Elixirgen Scientific (now Ricoh Biosciences, Inc.) manufactures and sells iPSC-derived human cells (neurons, astrocytes, microglia), differentiation kits, and maintenance media/reagents, and provides custom iPSC differentiation, novel cell type development, disease modeling, and assay services. Its proprietary platform uses transcriptomic benchmarking (bulk and single-cell RNA-seq) and optimized culture protocols to generate physiologically relevant human cell models for drug discovery and disease research.

Product overview

Elixirgen Scientific (now Ricoh Biosciences) offers a unified portfolio of iPSC-based products and services for drug discovery. The core offering includes Quick-Neuron and Quick-Glia iPSC-derived cell products (excitatory, cholinergic, dopaminergic, GABAergic, and motor neurons, plus astrocytes and microglia), differentiated using SeV (Sendai virus) and mRNA-based protocols. These are complemented by rapid differentiation kits enabling labs to generate cells in 1-2 weeks. Services include custom iPSC differentiation, novel cell type development, disease modeling (Alzheimer's and ALS), custom assays, multielectrode array (MEA), and calcium flux assays. The proprietary platform technology uses transcriptomic benchmarking (RNA-seq), transcription factors, and optimized culture conditions for robust, scalable manufacturing.

Differentiator

Problem solved

Functional benefit

Products and services

• Quick-Neuron Excitatory Neurons (iPSC-Derived) Human iPSC-derived excitatory neurons from healthy control donors, intended for disease modeling, drug discovery, and neuroscience research.
• Quick-Neuron Cholinergic Neurons (iPSC-Derived) Human iPSC-derived cholinergic neurons from healthy control donors, suitable for neurological research and therapeutic screening.
• Quick-Neuron Dopaminergic Neurons (iPSC-Derived) Human iPSC-derived dopaminergic neurons produced via mRNA differentiation, used for Parkinson's disease modeling and related research.
• Quick-Neuron GABAergic Neurons (iPSC-Derived) Human iPSC-derived GABAergic neurons differentiated using mRNA-based protocols, for inhibitory neuron research and drug discovery.
• Quick-Neuron Motor Neurons (iPSC-Derived) Human iPSC-derived motor neurons for ALS research and neuromuscular disease modeling, including patient-derived ALS motor neuron models for TDP-43 mislocalization studies.
• Quick-Glia Astrocytes (iPSC-Derived) Human iPSC-derived astrocytes (Quick-Glia) from healthy control donors for neurobiology research and astrocyte-related disease modeling.
• Quick-Glia Microglia (iPSC-Derived) Human iPSC-derived microglia (Quick-Glia) for neuroinflammation studies and brain disease modeling applications.
• Quick-Neuron Sensory Neurons (iPSC-Derived) Human iPSC-derived sensory neurons for peripheral nervous system research and pain mechanism studies.
• Neural Precursor Cells (iPSC-Derived) Human iPSC-derived neural precursor cells for developmental biology research and directed differentiation protocols.
• Astrocyte Differentiation Kit (SeV) SeV-based kit for differentiating human iPSCs into astrocytes in 1-2 weeks, designed for lab implementation.
• Excitatory Neuron Differentiation Kit (SeV) SeV-based kit for rapid differentiation of human iPSCs into excitatory neurons within 1-2 weeks.
• Cholinergic Neuron Differentiation Kit (SeV) SeV-based differentiation kit for generating cholinergic neurons from human iPSCs in 1-2 weeks.
• GABAergic Neuron Differentiation Kit (mRNA) mRNA-based kit for differentiating human iPSCs into GABAergic inhibitory neurons.
• Motor Neuron Differentiation Kit (SeV) SeV-based kit for generating motor neurons from human iPSCs, suitable for ALS and neuromuscular disease research.
• Sensory Neuron Differentiation Kit (mRNA) mRNA-based differentiation kit for producing sensory neurons from human iPSCs.
• Skeletal Muscle Differentiation Kit (SeV) SeV-based kit for differentiating human iPSCs into skeletal muscle cells for muscular disease research.
• Custom iPSC Differentiation Service Custom differentiation service applying Ricoh Biosciences' protocols to customer-provided iPSC lines to generate decision-ready differentiated cells within weeks.
• Novel Cell Type Development Service Development service for creating new cell types when no existing products meet research needs, building custom differentiation protocols.
• Disease Modeling Service Patient-derived iPSC disease modeling service for Alzheimer's disease and ALS, providing physiologically relevant human cell models for pre-clinical drug testing.
• Custom Assay Services Custom assay development services using iPSC-derived cells as substrates, delivering data-ready results for specific experimental needs.
• Multielectrode Array (MEA) Service Electrophysiology recording service using multielectrode array technology to assess neuronal network function and drug responses.
• Calcium Flux Assays Service Calcium imaging and flux assay services for measuring neuronal activity and signaling pathways in iPSC-derived cells.

Quantifiable outcome

• Specialized human cells generated in 1-2 weeks
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• DefiniGEN: Emerging iPSC-derived hepatocyte and metabolic disease model provider; comparable custom iPSC differentiation services business model targeting drug discovery workflows.
• Brainxell: Emerging iPSC-derived neural cell provider (dopaminergic, GABAergic, motor neurons) closely overlapping with Ricoh Biosciences' neuroscience catalog; competes for the same neurodegenerative research and screening programs.
• Bit Bio: Emerging iPSC player commercializing ioCells (glutaminergic neurons, GABAergic neurons, myocytes) via proprietary opti-ox precision reprogramming; overlaps with Ricoh Biosciences' Quick-Neuron catalog and pharma tools positioning.
• Censo Biotechnologies: Emerging iPSC services provider offering iPSC generation, banking, and differentiation for pharma and academic clients; competes most directly with Ricoh Biosciences' custom differentiation and disease modeling services.

Direct peers

• Ncardia: Direct peer offering iPSC-derived cardiomyocytes and neurons plus custom differentiation services for drug discovery; comparable catalog-plus-services business model targeting similar pharma customers.
• REPROCELL: Direct peer offering iPSC-derived neural and cardiac cells plus stem cell reagents; similarly focused on drug discovery applications and competing in the same pharma and academic accounts.
• Axol Bioscience: Direct peer specializing in iPSC-derived neural and immune cell products and custom services; comparable product portfolio including neural precursors and a similar academic-to-pharma commercial approach.
• FUJIFILM Cellular Dynamics: Direct peer and the largest iPSC-derived cell manufacturer, offering catalog iPSC-derived neurons, cardiomyocytes, hepatocytes and endothelial cells with global distribution — the same core product category as Ricoh Biosciences.

Broad incumbents

• STEMCELL Technologies: Broad incumbent supplying stem cell reagents, media, and differentiation kits; competes with Ricoh Biosciences on kits, reagents, and maintenance media across academic and pharma accounts.
• Thermo Fisher Scientific (Gibco Cell Therapy): Broad incumbent supplying Gibco-branded iPSC-derived cells, differentiation media, and reagents alongside a much larger life sciences portfolio; competes with Ricoh Biosciences for both catalog purchases and pharma services contracts.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• YouTubeyoutube.com/@RicohBiosciences
• LinkedInlinkedin.com/company/ricoh-biosciences
• Xx.com/elixirgensci
• Facebookfacebook.com/elixirgensci

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elixirgen Scientific